

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6242367

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CARNOT, LLC	08/10/2020
RECEIVING PARTY DATA	
Name:	ARCUATE THERAPEUTICS, INC.
Street Address:	200 BERKELEY STREET
City:	BOSTON
State/Country:	MASSACHUSETTS
Postal Code:	02116
PROPERTY NUMBERS Total: 5	
Property Type	Number
Application Number:	62321168
Application Number:	16092093
Application Number:	62835859
Application Number:	62813299
Application Number:	62858040
CORRESPONDENCE DATA	
Fax Number:	(617)856-8201
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-856-8200
Email:	ip@brownrudnick.com, srichards@brownrudnick.com
Correspondent Name:	BROWN RUDNICK, LLP
Address Line 1:	ONE FINANCIAL CENTER
Address Line 4:	BOSTON, MASSACHUSETTS 02111
ATTORNEY DOCKET NUMBER:	35719/3, 4, 11, 12, 13
NAME OF SUBMITTER:	ADAM M. SCHOEN
SIGNATURE:	/ADAM M. SCHOEN/
DATE SIGNED:	08/10/2020
Total Attachments: 5	
source=CARN-ARCU-conf-asmt-signed#page1.tif	

source=CARN-ARCU-conf-asmt-signed#page2.tif

source=CARN-ARCU-conf-asmt-signed#page3.tif

source=CARN-ARCU-conf-asmt-signed#page4.tif

source=CARN-ARCU-conf-asmt-signed#page5.tif

CONFIRMATORY ASSIGNMENT

WHEREAS Assignor,

CARNOT, LLC

hereinafter referred to as "Assignor", has previously assigned all rights, title, and interest to the "Invention(s)," set forth in Exhibit A, including the right to file applications for patent of any country on the Inventions; any application for patent of any country claiming priority to these applications; any provisional or other right to recover damages, including royalties, for prior infringements of these patents applications; and any patent of any country that may be granted therefor or thereon, to

ARCUATE THERAPEUTICS, INC.

hereinafter referred to as "Assignee", a Delaware corporation whose post office address is 200 Berkeley St., Boston, MA 02116 (the "Assignee"), in one or more Prior Assignments recorded with the United States Patent and Trademark Office at reel and frame numbers set forth in Exhibit A.

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, and to the extent that the Assignor has not done so already via a prior assignment with the Assignee, Assignor hereby executes this Confirmatory Assignment to sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns, the Assignor's entire right, title, and interest in:

- (a) the Invention(s);
- (b) the applications and patents identified in Exhibit A;
- (c) the right to file applications for patent of any country on the Invention(s), including all rights under the Paris Convention for the Protection of Industrial Property and under the Patent Cooperation Treaty;
- (d) any application(s) for patent of any country claiming the Invention(s);
- (e) any application(s) for patent of any country claiming priority to the application for patent identified in Exhibit A or any application(s) for patent claiming the Invention(s), including any division(s), continuation(s), and continuation(s)-in-part; and
- (f) any provisional or other right to recover damages, including royalties, for prior infringements of any application for patent identified in the preceding paragraphs (b)-(e); and

(g) any patent(s) of any country that may be granted for or on any application for patent identified in the preceding paragraphs (b) – (e), including any reissue(s) and extension(s) of said patent(s).

The above-granted rights, titles, and interests are to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made.

The Assignor hereby represents to the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, or if applicable, at such time said prior agreement was executed, the Assignor is a lawful owner of an undivided interest in the entire right, title, and interest in and to the Invention(s), that the Invention(s) are unencumbered, except, if applicable, by obligation to assign in accordance with said prior agreement, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner set forth herein.

The Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that the Assignor will sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done in connection with any and all proceedings for the procurement, maintenance, enforcement and defense of the Invention(s), said applications, and said patents, including interference proceedings, without charge to the Assignee, its successors, legal representatives, and assigns, but at the cost and expense of the Assignee, its successors, legal representatives, and assigns.

The Assignor hereby requests the patent authority to issue/grant said patents of their respective country to the Assignee for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.


Date: August 10, 2020

By: 
CARNOT, LLC

Print Name: Andrew Levin

Title at Assignor: President

Date: August 10, 2020

By: 
Witness Signature

By: Sara McMenimen
Witness Name

Date: Aug 8, 2020

By: Timothy Noyes
ARCUATE THERAPEUTICS, INC.

Print Name: Timothy Noyes

Title at Assignee: CEO

Date: _____

By: _____
Witness Signature

By: _____
Witness Name

EXHIBIT A

Docket No.	Jurisdiction	Application No.	Filing Date	Publication No.	Title
ARCU-002/00US 35719/3	USA	62/321168	11-Apr-16	n.a.	Chiral Peptides
ARCU-002/01AU 35719/9	Australia	2017249218	10-Apr-17	2017249218	Chiral Peptides
ARCU-002/01CA 35719/8	Canada	3020393	10-Apr-17	3020393	Chiral Peptides
ARCU-002/01CN 35719/7	China	201780031671.6	10-Apr-17	CN109563131A	Chiral Peptides
ARCU-002/01EP 35719/5	EPO	17782934.8	10-Apr-17	EP3442990	Chiral Peptides
ARCU-002/01JP 35719/6	Japan	2019-503646	10-Apr-17	2019-523260	Chiral Peptides
ARCU-002/01US 35719/4	USA	16/092093	8-Oct-18	US2019/0153032	Chiral Peptides
ARCU-002/01WO 35719/10	PCT	PCT/US2017/026869	10-Apr-17	WO2017/180535	Chiral Peptides
ARCU-003/00US 35719/11	USA	62/835859	18-Apr-19	n.a.	Methods of Treating Renal Conditions Using Peptides that Improve Mitochondrial Function
ARCU-003/01WO 35719/16	PCT	PCT/US2020/027898	13-Apr-2020	n.a.	Methods of Treating Renal Conditions Using Peptides that Improve Mitochondrial Function
ARCU-004/00US 35719/12	USA	62/813299	4-Mar-19	n.a.	Pharmaceutical Compositions Containing Free Bases and Methods of Use Thereof
ARCU-004/01US 35719/13	USA	62/858040	6-Jun-19	n.a.	Pharmaceutical Compositions Containing Free Bases and Methods of Use Thereof
ARCU-004/03WO 35719/15	USA	PCT/US2020/020913	4-Mar-20	n.a.	Pharmaceutical Compositions Containing Free Bases and Methods of Use Thereof

63829825 v1